NUCB2

Across TCGA pan-cancer cohorts, NUCB2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of NUCB2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where NUCB2 RNA is repressed in tumor relative to normal tissue. In most cancer types NUCB2 is over-expressed in tumor, although a few such as HNSC and THCA show the opposite, repressed pattern.

HNSC, KIRC, and THCA are the cancer types where NUCB2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NUCB2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	−1.373	<.001	12	view →
KIRC	Female	IV	+1.183	<.001	12	view →
THCA	Male	III,IV	−1.832	<.001	11	view →
LIHC	Male	II,III,IV	+1.328	<.001	8	view →
BRCA	All	III,IV	+0.925	<.001	8	view →
BLCA	All	IV	−0.898	.002	6	view →
CHOL	All	All	+1.138	.003	5	view →
LUAD	All	All	+0.339	<.001	5	view →
KICH	All	All	+0.759	<.001	4	view →
KIRP	All	II,III,IV	+0.554	.016	4	view →
READ	Female	All	−1.134	.003	2	view →
LUSC	Male	III,IV	−0.702	.015	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

NUCB2–HNSC

Open the HNSC breakdown →